Asahi Kasei Therapeutics receives FDA approval for HSV drug acquired in $1 billion deal

Asahi Kasei Therapeutics announced that the U.S. Food and Drug Administration granted approval for its herpes simplex virus (HSV) therapy.

The drug, called Hovilpri, was purchased by Asahi Kasei earlier this year in a transaction valued at nearly $1 billion, underscoring the company's strategic move into antiviral medicines.

The approval gives the Japanese firm a new product in the U.S. market and could broaden its revenue base while providing clinicians with an additional option for treating HSV infections.